NCT02658734 - A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

December 14, 2019

Study Completion Date

December 14, 2019

Conditions

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Interventions

DRUG

Trastuzumab emtansine

3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks

Trial Locations (13)

Max Super Speciality Hospital, New Delhi

Indraprastha Apollo Hospitals, New Delhi

Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi

Max Super Speciality Hospital; Medical Oncology, North WEST Delhi

Artemis Health Institute, Gūrgaon

Fortis Memorial Research Institute; Department of Medical Oncology & Haematology, Gūrgaon

Apollo Hospitals International Limited, Gandhinagar

Tata Memorial Hospital; Dept of Medical Oncology, Mumbai

Jehangir Hospital, Pune

Manipal Hospital; Department of Oncology, Bangalore

Healthcare Global Enterprises Limited, Bangalore

Christian Medical College & Hospital; Medicine, Vellore

Sir Gangaram Hospital; Medical Oncology, New Delhi

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY